THE SHORT ANSWER
Does Anthem Cover Wegovy?
Coverage Is Highly Variable
Many Anthem commercial plans exclude GLP-1s (a class of weight loss medications) prescribed solely for weight loss. However, some employer or exchange plans cover Wegovy as a non-preferred drug. These plans require strict prior authorization (pre-approval from your insurer).[1]
Anthem Blue Cross isn't a single insurance policy—it's a collection of different plans across states, employers, and product lines. Coverage depends on:
- Your specific Anthem entity (e.g., Anthem Blue Cross in California vs. Anthem Blue Cross Blue Shield in Virginia)
- Your employer's chosen benefits (self-funded employers can customize coverage)
- The pharmacy benefit manager (PBM) and its formulary (approved drug list) used by your plan
- Your plan type (commercial employer, health exchange, Medicaid, or Medicare Advantage)
Bottom line: You must check your exact formulary and benefit documents. Don't assume coverage based on "Anthem" alone—two Anthem members in the same state can have completely different coverage.
For a complete overview of getting Wegovy covered regardless of insurer, see our full coverage guide.
PLANS, FORMULARIES & PBMS
How Anthem Decides Coverage
Understanding how Anthem makes coverage decisions helps you navigate the system:
Unlike Kaiser, Anthem Doesn't Employ Doctors
This is a key distinction. Kaiser Permanente is an integrated health system where doctors and insurance are part of the same organization. Anthem is a traditional insurer—coverage is driven by:
- Formulary tier placement (preferred, non-preferred, or excluded)
- Prior authorization criteria set by Anthem's pharmacy team
- Employer benefit decisions (what coverage the employer purchased)
This means your doctor wanting to prescribe Wegovy doesn't guarantee coverage. Anthem decides based on plan rules, not clinical preference.
Anthem Formulary Tiers Explained
| Tier | What It Means | Typical Wegovy Status |
|---|---|---|
| Preferred | Lowest cost-sharing, easiest access | Rare—only some commercial HMO/PPO plans[1] |
| Non-Preferred | Higher cost-sharing, often requires PA | Common on exchange plans, Medicaid[1] |
| Excluded | Not covered under any circumstances | Many plans exclude weight loss drugs entirely |
How to Check Your Anthem Formulary
- Log into your Anthem member portal at anthem.com
- Go to "Pharmacy" then "Drug List" or "Formulary"
- Search for "Wegovy" or "semaglutide"
- Note the tier, PA requirements, and quantity limits
- Download your plan's full formulary PDF for complete details
Can't find it? Call the number on your Anthem ID card and request your formulary in writing.
Call Script for Anthem
"Hi, I'm calling to check coverage for a prescription medication. My member ID is [NUMBER]. I need to know:
- Is Wegovy (semaglutide) covered on my plan's formulary for weight management?
- What tier is it on?
- Is prior authorization required?
- What are the coverage criteria—BMI (body mass index), comorbidities (related health conditions), step therapy?
- Can you send me the coverage policy in writing?"
WHAT TO EXPECT BY PLAN TYPE
Anthem's 2025 Wegovy Coverage
Here's the realistic coverage landscape for Anthem members in 2025:
Coverage by Plan Type and Region
| Plan Type | 2025 Status | PA/Step Therapy (see below) | Notes |
|---|---|---|---|
| Commercial HMO/PPO/POS | Varies | Yes, if covered | Some plans cover as preferred tier[1] |
| Commercial Employer | Varies by employer | Yes, if covered | Self-funded employers can customize; ask HR |
| Fully-Insured Large Group | Often excluded | N/A | Many ended GLP-1 weight loss coverage 1/1/2025[2] |
| Health Exchange (ACA) | Rarely covered | Yes, if covered | Most ACA plans exclude obesity-only GLP-1s; some cover with strict PA[1] |
| Managed Medicaid HMO | Varies by state | Yes | Some states cover non-preferred, some exclude[1] |
| Medicare Advantage (MA-PD) | Bridge only | N/A | Basic Part D coverage excludes weight-loss drugs by statute[1]; the Medicare GLP-1 Bridge covers Wegovy for $50 per monthly fill (with conditions) |
| Medicare PDP | Bridge only | N/A | The same exclusion applies to the plan's basic Part D coverage; the Medicare GLP-1 Bridge is separate (outside Part D) |
2025 GLP-1 Coverage Rollbacks
Major Coverage Changes in 2025
Several Blue Cross/Blue Shield plans (including some Anthem affiliates) are tightening or eliminating GLP-1 weight loss coverage in 2025 due to cost concerns:
- Blue Cross Blue Shield of Michigan: Ended all GLP-1 weight loss coverage for fully-insured large groups on 1/1/2025[2]
- Blue Shield of California: Since January 1, 2025 (or plan renewal), some Blue Shield of California plans cover weight-loss drugs only for Class III obesity (BMI 40+), with a weight-loss program[3]
- BCBS of Massachusetts: Blue Cross Blue Shield of Massachusetts excludes Saxenda, Wegovy and Zepbound from January 1, 2026; spent $300M+ on GLP-1s in 2024[4]
While these are BCBS affiliates, the cost pressures apply industry-wide. Check your specific Anthem plan for current status.
State-by-State Anthem Coverage
Anthem operates under different names in different states. Here's what we know:
| State | Anthem Entity | Coverage Notes |
|---|---|---|
| California | Anthem Blue Cross | Some commercial plans cover with PA; check specific plan[5] |
| Virginia | Anthem BCBS | Coverage varies by plan; PA required for GLP-1s |
| Ohio | Anthem BCBS | Updated GLP-1 documentation requirements Oct 2025[6] |
| Georgia | Anthem BCBS | Coverage varies by plan type; commercial most likely |
| Indiana | Anthem BCBS | PA required for all GLP-1s; verify your specific plan |
| New York | Anthem BCBS | State-specific drug list available[7] |
This table reflects general trends—coverage policies change frequently. Always verify with your specific Anthem plan.
ANTHEM CRITERIA FOR WEGOVY
Prior Authorization Requirements
When Anthem does cover Wegovy, prior authorization is always required. Typical criteria:
- BMI ≥30 (or ≥27 with hypertension, type 2 diabetes, sleep apnea, etc.)
- 3-6 months documented lifestyle efforts (diet and exercise in your medical record)
- No concurrent GLP-1 use (can't take Ozempic, Wegovy at same time)
- Step therapy (trying other medications first): Some plans require trying other weight loss drugs before approving Wegovy
- Renewal: Must show ≥5% weight loss to continue coverage
For complete documentation checklists and PA preparation: Wegovy Prior Authorization Guide →
Your GLP-1 coverage,
denied approved
If Anthem denies your Wegovy, Honest Care can help you build a strong appeal with evidence-backed documentation.
Denied by Anthem?
Get Help NowCLINICAL VS. COVERAGE DECISIONS
Why Your Doctor's Answer May Differ
"My Doctor Says Yes, Anthem Says No"
Your doctor determining Wegovy is "medically appropriate" doesn't mean Anthem will pay for it. These are separate decisions made by different people with different criteria.
Here's why this disconnect happens:
| Your Doctor's Perspective | Anthem's Perspective |
|---|---|
| "Is this clinically appropriate for this patient?" | "Does this meet our documented criteria?" |
| Based on clinical judgment and guidelines | Based on formulary rules and policy documents |
| Considers individual patient circumstances | Applies standardized criteria to all members |
| Goal: What's best for this patient? | Goal: What meets documented criteria? |
What To Do About It
- Get specific criteria from Anthem—request the exact PA requirements in writing
- Work with your doctor to ensure documentation meets Anthem's standards, not just clinical standards
- Document everything—Anthem reviewers only see what's in the paperwork
- Don't just resubmit—if denied, address the specific denial reason with new documentation
Ask Your Doctor For Detailed Notes
A brief PA note won't succeed. Your doctor needs to include:
- Specific measurements (current BMI, weight history)
- ICD-10 codes (diagnosis codes used for billing) for all qualifying conditions
- Details of failed lifestyle interventions
- Impact of obesity on daily functioning
- Why Wegovy specifically (not just "any GLP-1")
YOUR OPTIONS
If Anthem Denies Wegovy
Appeals Can Work
65%+ of appealed prior authorization denials are overturned with strong documentation. Even for formulary exclusions, exception requests can succeed.[8]
Common Anthem denial reasons for Wegovy:
- Formulary exclusion / excluded benefit → Denial Guide
- Medical necessity not met → Medical Necessity Guide
- Step therapy required → Denial Guide
Anthem Appeal Basics
- Deadline: Typically 180 days from denial to file internal appeal (check your denial letter for exact deadline)
- Tip: Ask your doctor to request a peer-to-peer review with Anthem's medical director (if available)
- "Excluded benefit"? Consider self-pay options (Wegovy has no sleep apnea indication, so OSA isn't a Wegovy route)
For complete appeal strategies: Wegovy Appeals Guide →
ALTERNATIVES
If Anthem Won't Cover Wegovy
Sleep Apnea (OSA)
Note: Wegovy is not FDA-approved for sleep apnea—only Zepbound has that indication (December 20, 2024). Wegovy has no FDA-approved sleep apnea indication, so an OSA coverage pathway doesn’t apply to Wegovy; if you have OSA, ask your doctor whether Zepbound is appropriate.
Other options if coverage isn't available:
- Self-pay: NovoCare offers Wegovy at $349/month ($399 for Wegovy HD 7.2 mg) (reduced from $499 in Nov 2025) → Wegovy Cost Guide
- Compare medications: Wegovy vs Ozempic, Mounjaro & more → Wegovy Overview
- Switch plans: Check other insurers during open enrollment
WHAT'S CHANGING
2026 Outlook
Anthem's plan-by-plan coverage approach continues in 2026. Key Anthem-specific changes to watch:
- CarelonRx formulary updates: Anthem's PBM (formerly IngenioRx) may adjust tier placement and PA requirements—verify your 2026 formulary
- Anthem Medicare Advantage: Members can use the Medicare GLP-1 Bridge ($50 per monthly fill, July 1, 2026 – December 31, 2027) — see Medicare guide
- State variation continues: No unified national Anthem policy expected; check your specific state/plan
- More rollbacks possible: Following BCBS Michigan and Massachusetts cuts, some Anthem affiliates may tighten coverage
For Medicare and self-pay updates: Medicare Coverage Guide | Wegovy Cost Guide
ANTHEM & GLP-1 MEDICATIONS
Frequently Asked Questions
It depends on your specific plan. Many Anthem commercial plans exclude GLP-1s prescribed solely for weight loss, while some employer or exchange plans cover Wegovy as a non-preferred drug with strict prior authorization criteria. You must check your exact formulary—two Anthem members in the same state can have completely different coverage.
Wegovy is FDA-approved for chronic weight management and cardiovascular risk reduction—not diabetes. For type 2 diabetes, the same active ingredient (semaglutide) is sold as Ozempic, which typically has better insurance coverage. If you have type 2 diabetes, ask your doctor about Ozempic instead.
Anthem typically follows FDA label criteria: BMI ≥30 (obesity) or BMI ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension (high blood pressure), high cholesterol, or obstructive sleep apnea. Some plans may have stricter requirements. Request your plan's specific PA criteria in writing.
Some Anthem and Blue Cross plans are rolling back GLP-1 weight loss coverage due to cost concerns. BCBS Michigan ended coverage for fully-insured large groups on 1/1/2025. BCBS Massachusetts spent over $300M on GLP-1s in 2024 and excluded Wegovy, Zepbound and Saxenda for obesity from 1/1/2026. This isn't universal—check your specific plan.
Yes. Formulary and coverage policies can change at plan renewal (typically January 1 or your employer's renewal date). If you're currently covered, you may receive notice of formulary changes before renewal. Always re-verify coverage at the start of each plan year.
Some states have proposed laws requiring coverage of obesity treatments, but these mandates vary and may not apply to all plan types. Self-funded employer plans (where the employer pays claims directly rather than buying insurance) are regulated by federal law, not state law, so state mandates often don't apply to them. State mandates typically affect fully-insured individual and small group plans.
Initial PA approval is typically for 5-6 months depending on your plan. Re-authorization usually requires demonstrating ≥5% weight loss or continued progress. Renewal periods vary by plan—check your PA approval letter for specific dates and requirements.
No. Wegovy is not FDA-approved for sleep apnea—only Zepbound (tirzepatide) received that indication in December 2024, so an OSA coverage pathway doesn’t apply to Wegovy. If you have moderate-to-severe obstructive sleep apnea, ask your doctor whether Zepbound is appropriate.
YOUR PATH FORWARD
What's Next
Wegovy Coverage: Other Major Insurers
See how other insurers compare on Wegovy coverage:
- Blue Cross Blue Shield — Different from Anthem; major 2026 changes
- UnitedHealthcare — Coverage varies by plan; many require PA
- Cigna — Cigna plans may require step therapy; check your plan’s policy
- Aetna — Most plans cover with prior authorization
- Kaiser Permanente — Regional variations; often restrictive
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedReferences
- PrescriberPoint. (2025). "Anthem Blue Cross and Blue Shield Plans That Cover Wegovy." prescriberpoint.com
- Blue Cross Blue Shield of Michigan. (2024). "Changes coming for select weight loss drugs for some commercial members." Provider Alert. bcbsm.com
- Blue Shield of California. (2024). "Weight Loss Drug Exclusion Fact Sheet." blueshieldca.com
- Blue Cross Blue Shield of Massachusetts. (2025). "Blue Cross Blue Shield of Massachusetts Announces Latest Results." Reports GLP-1 spending exceeded $300M in 2024. bluecrossma.com
- Anthem Blue Cross California. (2025). "Prior Authorization Requirements." providers.anthem.com
- Anthem Provider News Ohio. (2025). "Important update: required documentation for select ePA requests." Confirms GLP-1 medications require attached documentation for ePA. providernews.anthem.com
- Anthem. (2025). "New York Drug List." anthem.com
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" ama-assn.org (Medicare Advantage data; 65%+ is a conservative estimate for commercial insurance); U.S. GAO. (2011). "Private Health Insurance: Data on Application and Coverage Denials." GAO-11-268. gao.gov
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.